Literature DB >> 8678045

Circulating anti-Helicobacter pylori immunoglobulin A antibodies and low serum pepsinogen I level are associated with increased risk of gastric cancer.

A Aromaa1, T U Kosunen, P Knekt, J Maatela, L Teppo, O P Heinonen, M Härkönen, M K Hakama.   

Abstract

Helicobacter pylori infection has been suggested to be associated with an increased risk of gastric cancer, and low levels of serum pepsinogen I (PG I) have been linked to atrophic gastritis, which is a risk factor for gastric cancer. In Finland, 39,268 persons from 25 cohorts participated during 1968-1972 in a health examination survey and were followed for up to 13 years. A nested case-control study was performed on 84 stomach cancer patients identified from the Finnish Cancer Registry and 146 controls matched for age, sex, and municipality. Serum samples drawn at the baseline study were analyzed. An elevated level of serum anti-H. pylori immunoglobulin A (IgA) antibodies (a titer > or = 70) and a low serum PG I level ( < 49 micrograms/liter) were associated with an increased risk of gastric cancer. The odds ratios were 2.52 (95% confidence interval (CI) 1.14-5.57) for high IgA and 2.68 (95% CI 1.35-5.30) for low PG I. For high immunoglobulin G (IgG) ( > or = 700), the odds ratio was only 1.50 (95% CI 0.70-3.22). When both high IgA and low PG I were present, the odds ratio was 5.96 (95% CI 2.02-17.57). The association of H. pylori infection with cancer became stronger with longer follow-up times, whereas that of low PG I was strongest at shorter follow-up times. Our findings support the hypothesis that H. pylori infection is a prevalent and potentially preventable cause of gastric cancer. They stress the value of IgA antibody determinations and provide new evidence for a pathogenesis leading from prolonged infection through atrophic gastritis to gastric cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8678045     DOI: 10.1093/oxfordjournals.aje.a008901

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  21 in total

1.  Gastric cancer screening using the serum pepsinogen test method.

Authors:  Kazumasa Miki
Journal:  Gastric Cancer       Date:  2006-11-24       Impact factor: 7.370

Review 2.  Diet, H pylori infection and gastric cancer: evidence and controversies.

Authors:  Alba Rocco; Gerardo Nardone
Journal:  World J Gastroenterol       Date:  2007-06-07       Impact factor: 5.742

3.  Helicobacter pylori infection and gastric cancer. A nested case-control study in a rural area of Japan.

Authors:  Y Watanabe; J H Kurata; S Mizuno; M Mukai; H Inokuchi; K Miki; K Ozasa; K Kawai
Journal:  Dig Dis Sci       Date:  1997-07       Impact factor: 3.199

4.  Clinical implications and characteristics of factor forkhead box protein 3 in gastric cancer.

Authors:  Changli Jiang; Weihua Wang; Wei Yan; Yuhai Zhang; Jiangtao Yang; Song Zhang; Cun Zhang; Wei Zhang; Wei Han; Junzhi Wang; Ying-Qi Zhang
Journal:  Exp Ther Med       Date:  2011-05-12       Impact factor: 2.447

Review 5.  Ethnic differences in gastric cancer genetic susceptibility: allele flips of interleukin gene.

Authors:  Juwon Kim; Yoonjung Kim; Kyung-A Lee
Journal:  World J Gastroenterol       Date:  2014-04-28       Impact factor: 5.742

6.  The role of serum pepsinogen in the detection of gastric cancer.

Authors:  Nayoung Kim; Hyun Chae Jung
Journal:  Gut Liver       Date:  2010-09-24       Impact factor: 4.519

7.  Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).

Authors:  M Dinis-Ribeiro; M Areia; A C de Vries; R Marcos-Pinto; M Monteiro-Soares; A O'Connor; C Pereira; P Pimentel-Nunes; R Correia; A Ensari; J M Dumonceau; J C Machado; G Macedo; P Malfertheiner; T Matysiak-Budnik; F Megraud; K Miki; C O'Morain; R M Peek; T Ponchon; A Ristimaki; B Rembacken; F Carneiro; E J Kuipers
Journal:  Virchows Arch       Date:  2011-12-22       Impact factor: 4.064

8.  Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).

Authors:  M Dinis-Ribeiro; M Areia; A C de Vries; R Marcos-Pinto; M Monteiro-Soares; A O'Connor; C Pereira; P Pimentel-Nunes; R Correia; A Ensari; J M Dumonceau; J C Machado; G Macedo; P Malfertheiner; T Matysiak-Budnik; F Megraud; K Miki; C O'Morain; R M Peek; T Ponchon; A Ristimaki; B Rembacken; F Carneiro; E J Kuipers
Journal:  Endoscopy       Date:  2011-12-23       Impact factor: 10.093

9.  Association of Helicobacter pylori IgA antibodies with the risk of peptic ulcer disease and gastric cancer.

Authors:  Timo U Kosunen; Kari Seppala; Seppo Sarna; Arpo Aromaa; Paul Knekt; Jarmo Virtamo; Anniina Salomaa-Rasanen; Hilpi Rautelin
Journal:  World J Gastroenterol       Date:  2005-11-21       Impact factor: 5.742

10.  Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal, healthy stomach.

Authors:  Katsunori Iijima; Yasuhiko Abe; Ryosuke Kikuchi; Tomoyuki Koike; Shuichi Ohara; Pentti Sipponen; Tooru Shimosegawa
Journal:  World J Gastroenterol       Date:  2009-02-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.